MONTE ROSA THERAPEUTICS INC
GLUENASDAQUS Equity
$718.61▲ $34.78 (+4.84%)
Simulated price1h—
24h▲ 4.8%
7d▲ 4506.5%
14d▲ 3233.1%
30d▲ 3165.7%
1y▲ 16048.5%
🏦Market Cap
$246.16B
Large Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
61
Fair
Trading Snapshot
- Day Range
- $714.22 – $723.97
- 52-Week Range
- —
- Volume
- $2.95B
- Avg Volume
- $3.14B
- Shares Outstanding
- —
- Next Earnings
- Oct 23, 2026
Fundamentals Snapshot
- Annual Revenue
- $87.91B
- Last Q Revenue
- $22.66B
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own GLUE
- ✓High-growth profile — revenue up +37.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 78% gross margin and 18% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$87.91B▲ +36.0% YoY
Gross Margin (TTM)
77.6%▲ +4.1% YoY
Operating Income (TTM)
$31.91B▲ +36.0% YoY
Free Cash Flow (TTM)
$16.18B▲ +36.0% YoY
About MONTE ROSA THERAPEUTICS INC
A company profile for MONTE ROSA THERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
61/100
Analyst Price Target
ⓘAverage Target
$818.60
▲ +13.9% Upside
High Target$1,030.33
Low Target$673.07
Based on 36 analysts
Latest News & Updates
🚀
Bloomberg·2h ago
MONTE ROSA THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Bloomberg·5h ago
Analysts lift GLUE price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Bloomberg·1d ago
MONTE ROSA THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.